Macrocure (MCUR) vs. Supernus Pharmaceuticals (SUPN) Financial Survey
Macrocure (NASDAQ: MCUR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.
This is a breakdown of recent recommendations for Macrocure and Supernus Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Supernus Pharmaceuticals has a consensus target price of $48.33, indicating a potential upside of 9.97%. Given Supernus Pharmaceuticals’ higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Macrocure.
Valuation & Earnings
This table compares Macrocure and Supernus Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Supernus Pharmaceuticals||$252.59 million||8.82||$82.36 million||$1.95||22.54|
Supernus Pharmaceuticals has higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Macrocure has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Institutional & Insider Ownership
2.8% of Macrocure shares are held by institutional investors. Comparatively, 92.8% of Supernus Pharmaceuticals shares are held by institutional investors. 6.7% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Macrocure and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Supernus Pharmaceuticals beats Macrocure on 10 of the 10 factors compared between the two stocks.
Macrocure Company Profile
Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
Receive News & Stock Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related stocks with our FREE daily email newsletter.